Pallas Capital Backs Monte Rosa Therapeutics, Inc. (GLUE) Amid Growth Prospects

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) is among the best fast money stocks to buy now. During the second quarter, Pallas Capital Advisors acquired a new position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) through the purchase of 13,182 shares of the company’s stock. According to the latest filing with the SEC, the firm’s investment in the company is approximately $59,000.

There are many advocates for Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), and it comes as no surprise. The company has managed to strike another deal with Novartis, which involves both companies developing molecular glue degraders for immune-mediated disorders. This is yet another major highlight as it brings forth $120 million in proceeds, along with the potential to generate $5.7 billion in milestone payments.

If that weren’t already a strong case, Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has been awarded IND clearance from the FDA to accelerate MRT-8102, a second molecular glue degrader. As long as the company executes its initiatives successfully, we have a good reason to believe in the potential for this stock to be rewarding.

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) is a Massachusetts-based clinical-stage biotechnology company developing novel small-molecule precision medicines. Incepted in 2019, the company maintains a strategic partnership and licensing agreement with F. Hoffmann-La Roche Ltd.

While we acknowledge the potential of GLUE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.